Lilly’s New Weight Pill Gets U.K. Approval | Durham News

Eli Lilly’s new daily pill Foundayo just got U.K. approval — a major win as its first oral weight and diabetes drug in Europe. With no needles required and flexible dosing, it could unlock a massive market of patients avoiding injections. The GLP-1 drug orforglipron delivers real weight loss — up to 11.2% in trials — plus heart health benefits, without strict food rules. While Novo Nordisk already has an oral option, Foundayo’s lower price and potential NHS coverage could make it a game-changer — with a final decision expected in November 2026. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5867a57652c6752e